SUPERNUS PHARMACEUTICALS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $SUPN in the last 30 days.
See all $SUPN insider activity →Supernus Pharmaceuticals (SUPN) announced a merger with Indivior (INDV) and reported Q2 earnings. Revenue rose 32% to $219M, but net loss was $58M. The all-stock deal, pending approval, is expected to close Q4 2023. Stock closed 3% higher.
Zoetis (ZTS) reported flat Q2 revenue of $2.47B, missing estimates, and lowered full-year guidance. Supernus Pharmaceuticals (SUPN) reported 27.7% revenue growth to $211.3M, beating estimates. Eli Lilly (LLY) reported 47.7% revenue growth to $22.97B, significantly beating estimates. All three stocks have risen since reporting.
Macquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.
Over the past 7 days, alphai's AI scored 2 news stories mentioning SUPN (SUPERNUS PHARMACEUTICALS, INC.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent SUPN coverage spans mergers & acquisitions, earnings and market movers.
Merger creates a larger neurology and addiction portfolio; earnings beat revenue but miss profit, leading to mixed short‑term sentiment.
Strong beat could sustain upside momentum.
All-stock CNS merger terms can shift valuation and relative risk for SUPN based on exchange ratio expectations and synergy credibility.
Deal announcement creates a near-term repricing catalyst for SUPN, with merger-arb dynamics likely.
New merger agreement is a primary catalyst with potential valuation re-rating.
alphai scores every news story that mentions SUPN with an AI model for sentiment and relevance, and aggregates insider trades from SUPERNUS PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Supernus Pharmaceuticals (SUPN) announced a merger with Indivior (INDV) and reported Q2 earnings. Revenue rose 32% to $219M, but net loss was $58M. The all-stock deal, pending approval, is expected to close Q4 2023. Stock closed 3% higher.
3 min readZoetis (ZTS) reported flat Q2 revenue of $2.47B, missing estimates, and lowered full-year guidance. Supernus Pharmaceuticals (SUPN) reported 27.7% revenue growth to $211.3M, beating estimates. Eli Lilly (LLY) reported 47.7% revenue growth to $22.97B, significantly beating estimates. All three stocks have risen since reporting.
3 min readMacquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.
6 min readStocks settled sharply higher as Middle East tensions eased. The article cites a 66% chance of a +25 bp FOMC hike (Sept 15-16) and an 88% chance of an ECB +25 bp hike (Sept 10). WTI fell over 5%, lifting 10-year Treasuries and lowering yields. It also lists major movers including META (+6%), ORCL (+9%), and ATKR (+28%) after a $3.8B deal.
6 min readMarkets were mixed as investors priced a 63% chance of a 25 bp FOMC hike on Sept. 15-16. U.S. 10-year yields fell to 4.688% and German bunds and UK gilts moved lower. Airline and cruise stocks rose as WTI dropped over 6%. Software gained, while semiconductors and energy fell. Notable movers included ATKR (+28%) on a $3.8B Prysmian deal and CNH (+16%) raising EPS guidance.
7 min readMarkets rose as investors priced in easing geopolitical risks and US economic strength. The article cites a 63% chance of a +25 bp FOMC hike and notes US 10-year yields fell to 4.682%. It highlights stock moves including Meta (+5%), Amazon (+4%), and ATKR surging after Prysmian agreed to buy for $3.8B.
7 min readSupernus Pharmaceuticals and Indivior agreed to merge in a deal valued at about $1.8 billion. Indivior shareholders will receive 0.2683 Supernus shares each, a stated ~58% premium. Supernus shareholders will own ~58% and Indivior ~42%. Closing is expected in H2 2026, pending approvals, with ~$125 million annual cost synergies by end-2027.
3 min readIndivior (INDV) agreed to a tax-free, all-stock merger with Supernus (SUPN). Indivior shareholders will own about 56.5% and Supernus 43.5%. The combined CNS-focused company is expected to close in Q4 2026 and trade on Nasdaq under SUPN. Pro forma: ~$2.2B revenue, $888M adjusted EBITDA, $125M synergies. Indivior Q2 2026: adj. EPS $1.15, revenue $343M.
7 min readSupernus Pharmaceuticals and Indivior are planning an all-stock merger to form a CNS-focused biopharma. The deal is expected to produce pro forma net revenue of $2.2bn and about $125m in annual cost synergies. Supernus brings Qelbree and Gocovri; Indivior brings Sublocade, Suboxone and Opvee. If completed in Q4 2026, the combined firm will trade as SUPN on Nasdaq.
4 min readSupernus Pharmaceuticals (NASDAQ:SUPN) is set to report earnings Tuesday after market close. The prior quarter saw revenue of $207.7M, up 38.6% YoY, but EPS missed expectations. For the upcoming quarter, analysts expect revenue growth of 24.3% YoY. The article cites an average analyst price target of $63.50 versus a $45.01 share price.
3 min read
